%0 Journal Article
%T Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars
%A Gunter von Minckwitz
%A Hans-Christian Kolberg
%A Vladimir Hanes
%J Archive of "Oncotarget".
%D 2019
%R 10.18632/oncotarget.26528
%X ABP 980 (Amgen Inc, Thousand Oaks, CA, USA) is a biosimilar of trastuzumab, the recombinant humanized monoclonal antibody against human epidermal growth factor receptor-2 (HER-2), which is overexpressed in 15-30% of patients with breast cancer [1, 2] and 10-30% of patients with gastric tumors [2]. ABP 980 (KANJINTI£¿, Amgen Europe B.V., The Netherlands) was approved by the European Medicines Agency in March 2018 for the same indications as the originator biologic or reference product (RP), Herceptin£¿ (trastuzumab; Roche Registration GmbH, Germany), including treatment of HER2-positive (HER2+) metastatic breast cancer, HER2+ early breast cancer and HER2+ metastatic adenocarcinoma of the stomach or gastroesophageal junction [3, 4]
%K biosimilars
%K breast cancer
%K trastuzumab
%K ABP 980
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343751/